For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it. Transcription factors ...

A research team led by Prof. Liu Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Science has developed IHMT-15130, a selective and irreversible inhibitor of Bone ...

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously “undruggable” cancer protein target, permanently blocking it. Transcription factors ...

Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a co-factor that controls transcription by phosphorylating the C-terminal domain of ...

At the ongoing meeting of the American Chemical Society in Denver, F. Hoffmann-La Roche Ltd. has reported the discovery of an orally available and brain-penetrant irreversible asparagine-specific ...

A research team led by Prof. LIU Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Science has developed IHMT-15130, a selective and irreversible inhibitor of Bone ...

A phase II clinical trial to study the use of cabozantinib (cabo) in patients with hepatocellular carcinoma (HCC) post immunotherapy treatment. Cabozantinib (CABO) tolerance and efficacy for patients ...

Mitogen-Activated Protein Kinase (MAPK) signalling cascades are fundamental to the regulation of numerous cellular processes, including stress response, inflammation, cell cycle control and apoptosis.

In the article that accompanies this editorial, Colman et al 2 present the results of the randomized phase III STELLAR trial evaluating the combination of eflornithine, an irreversible inhibitor of ...